NasdaqCM - Nasdaq Real Time Price USD

Abeona Therapeutics Inc. (ABEO)

4.3500 -0.2100 (-4.61%)

At close: October 30 at 4:00:00 PM EDT

4.3500 0.0000 (0.00%)

After hours: October 30 at 4:10:36 PM EDT

Trade ABEO on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for ABEO

Previous Close 4.5600
Open 4.5000
Bid 3.2400 x 200
Ask 5.6800 x 200
Day's Range 4.3050 - 4.5300
52 Week Range 4.0000 - 7.6500
Volume 783,430
Avg. Volume 1,352,609
Market Cap (intraday) 248.75M
Beta (5Y Monthly) 1.30
PE Ratio (TTM) --
EPS (TTM) -1.1800
Earnings Date (est.) Nov 11, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 18.88
Motley Fool Rating Bullish

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

www.abeonatherapeutics.com

226

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ABEO

17.46%

S&P 500 (^GSPC)

10.73%

1-Year Return

ABEO

14.37%

S&P 500 (^GSPC)

11.11%

3-Year Return

ABEO

14.78%

S&P 500 (^GSPC)

81.91%

5-Year Return

ABEO

78.52%

S&P 500 (^GSPC)

64.59%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q1 FY26

Revenue 8.72M

Earnings -17.07M

Profit Margin -195.81%

FY25

FY26

50M

100M

0.0%

5000.0%

10000.0%

15000.0%

20000.0%

25000.0%

Analyst Price Targets

14.00

18.88 Average

4.3500 Current

30.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 9/18/2026

Analyst Cantor Fitzgerald

Rating Action Maintains

Rating Overweight

Price Action Raises

Price Target 28 -> 30

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

-246.42%
Return on Assets (ttm)

-24.55%
Return on Equity (ttm)

-43.13%
Revenue (ttm)

25.52M
Net Income Avi to Common (ttm)

-62.89M
Diluted EPS (ttm)

-1.1800

Balance Sheet and Cash Flow

Total Cash (mrq)

146.83M
Total Debt/Equity (mrq)

15.52%
Levered Free Cash Flow (ttm)

-73.4M

MREO Mereo BioPharma Group plc

0.2895 -4.08%

AKBA Akebia Therapeutics, Inc.

0.7065 -4.81%

ALDX Aldeyra Therapeutics, Inc.

0.5603 -14.99%

ABUS Arbutus Biopharma Corporation

4.2100 -1.64%

VSTM Verastem, Inc.

9.75 +0.93%

U.S. markets closed

Abeona Therapeutics Inc. (ABEO)

Trading disclosure

-1.14%

-17.14%

-20.33%

-17.46%

-14.37%

-78.52%

-100.00%

Abeona Therapeutics Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch